Kalaris Posts $0.46 Q3 GAAP Loss Per Share as Net Loss Narrows

Kalaris Therapeutics, Inc. narrowed its third-quarter net loss to $11.0 million and expects preliminary data from its TH103 study in the second half of 2027.

The GAAP loss was $0.46 per basic and diluted share, compared with $0.64 on each basis in the third quarter of 2025. Net loss was $11.9 million in that year-earlier quarter.

Cash, cash equivalents and marketable securities totaled $82.9 million at quarter-end. Kalaris expects those funds to support operations into 2028 based on its current operating plans.

A batch from the pilot manufacturer failed the aggregation release specification because of a batch-specific operational issue. A new batch of material is expected in the second quarter of 2027. Kalaris expects preliminary data from the Phase 1b/2 TH103 study in the second half of that year.